Literature DB >> 15790527

Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.

Wing Lok Au1, John R Adams, André R Troiano, A Jon Stoessl.   

Abstract

Over the past two decades, positron emission tomography (PET) has provided valuable insights into the mechanisms of nigrostriatal degeneration in Parkinson's disease (PD). Furthermore, it allows the in vivo assessment of disease progression and the evaluation of treatment interventions. In this review, we shall discuss some of the issues and concerns that arise with the use of PET as a surrogate marker of disease progression in Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15790527     DOI： 10.1016/j.molbrainres.2004.09.028

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN： 0169-328X


  10 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

Review 2.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 3.  Assessment of the progression of Parkinson's disease: a metabolic network approach.

Authors:  Thomas Eckert; Chengke Tang; David Eidelberg
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182

Review 4.  Update on Molecular Imaging in Parkinson's Disease.

Authors:  Zhen-Yang Liu; Feng-Tao Liu; Chuan-Tao Zuo; James B Koprich; Jian Wang
Journal:  Neurosci Bull       Date:  2017-12-27       Impact factor: 5.203

Review 5.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

Review 6.  Attention biases, anxiety, and development: toward or away from threats or rewards?

Authors:  Tomer Shechner; Jennifer C Britton; Koraly Pérez-Edgar; Yair Bar-Haim; Monique Ernst; Nathan A Fox; Ellen Leibenluft; Daniel S Pine
Journal:  Depress Anxiety       Date:  2011-12-13       Impact factor: 6.505

7.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

8.  The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling.

Authors:  Lisa Kuramoto; Jacquelyn Cragg; Ramachandiran Nandhagopal; Edwin Mak; Vesna Sossi; Raul de la Fuente-Fernández; A Jon Stoessl; Michael Schulzer
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

Review 9.  The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Authors:  Elizabeth A Mazzio; Fran Close; Karam F A Soliman
Journal:  Int J Mol Sci       Date:  2011-01-17       Impact factor: 5.923

10.  Robust Bayesian Analysis of Early-Stage Parkinson's Disease Progression Using DaTscan Images.

Authors:  Yuan Zhou; Sule Tinaz; Hemant D Tagare
Journal:  IEEE Trans Med Imaging       Date:  2021-02-02       Impact factor: 10.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.